We are urging all of our subscribers to add PLPL to their watchlist right now, and be ready to trade tomorrow morning when the clock strikes 9:30am EST!
About the Company:
PLPL (Plandaí Biotechnology, Inc.) and its subsidiaries develop highly phyto-available™ extracts. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare® extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical.
Products and Benefits:
"BIOAVAILABILITY" can be defined as a measurement of the amount of compound absorbed into the bloodstream.
In the market today, green tea high purity EGCG extracts, with an average selling price of $500/kg, have poor bioavailability of between 1-10%. PLPL's proprietary plant extracts have shown, in published studies, to have increased bioavailability. They believe through their studies that this is between 60-80%, far exceeding anything currently available today.
PLPL's extracts include but are not limited to, gallate catechins from green tea, (catechin gallate (CG),epigallocatechin gallate (EGCG), gallocatechin gallate (GCG), and epicatechin gallate (ECG); carotenoids (lycopene)from tomatoes, as well as citrus bioflavonoids and limonoids. Furthermore, Plandaí's gallate catechin extract will be the active ingredient in formulated products supporting weight loss, antiaging, the lowering of blood cholesterol, the regulation of high blood pressure and controlling diabetes 1 and 2.
This means, that PLPL's extracts deliver a more meaningful and beneficial dose at highly competitive prices to the consumer, in wellness terms
The Northern American and European natural extracts market are emerging and in a state of intense competition. The shift towards natural ingredients is driving the expansion of the natural extracts market. Among the flurry of ingredients competing in the natural extracts market, green tea extracts is a pioneer and one of the most prominent success stories.
Plandai Biotechnology, Inc. Announces 2nd Quarter Sales and Gives Forecast for Q3
Just over and hour ago, PLPL announced that it has sold and shipped over half a ton (640kg) of Phytofare® Catechin Complex to customers on four continents during the quarter ending March 31, 2016, its first full quarter of sales. The bulk of these sales were to customers in South Africa and Europe, with initial orders also being filled for Australia and India.
Callum Cottrell-Duffield, Vice President of Sales and Marketing for Plandaí Biotechnology, commented, "This past quarter represents the first quarter where we had full operating capacity and were able to establish significant sales in multiple territories. The hail storm last Spring set back our production and impacted our inventory, but we were able to launch our Phytofare® product regardless and start gaining traction in the markets. We've been able to steadily grow our customer base over the past six months and re-orders are growing month-to-month, both of which are positive signs for the future of Plandaí."
Addressing forecasts for the coming months, Mr. Cottrell-Duffield added, "Our immediate goal is to reach 500kg of sales per month, which, if month-to-month increases continue, should be easily attainable in Q3. By the end of the current fiscal year, we would like to be shipping over a ton (1,000kg) per month. We are in active discussions to expand our sales base to cover the remaining global markets, including North and South America and Asia, and expect to announce success on that front shortly."
Mr. Cottrell-Duffield continued, "Our product is definitely one of those that requires time to build a foothold in the marketplace since customer base is comprised of well-established supplement and nutrition product manufacturers. Adding Phytofare® to their products requires extensive in-house testing, then they have to change over all packaging and labeling. This then is followed by a new marketing program and product launch. So, it takes time and patience on everyone's part, but the momentum is rolling now and we're excited by the coming months."
It appears that PLPL's darkest days are now over, and now its time to capitalize on what looks like an inevitable uptrend for this once beaten down stock.
PLPL Receives Initial Order From Coyne Healthcare
Just 2 weeks ago, PLPL announced that it has received an initial order for 500,000 capsules of the company's Pheroid® entrapped Phytofare® catechin complex -- trade named "ph²™" from Coyne Healthcare, leading developer of high-quality nutraceutical and food supplements based in South Africa. PLPL previously announced that it had entered into a license and supply agreement with Coyne Healthcare to develop a new biopharmaceutical product using ph2TM under which Plandaí will prepare the capsules for Coyne who will then bottle, package and sell the product. Coyne Healthcare indicated that this initial order will be sold exclusively in South Africa but their intention is to expand the product internationally in the future.
The new Coyne Healthcare product represents the first application of ph²™ in a commercial product intended for human use. ph2™ is the combination of the nano-entrapment system, Pheroid®, with PLPL's Phytofare® catechin complex. Pheroid® encapsulates, or entraps, the Phytofare® in a colloidal emulsion which clinical tests have shown both improves absorption into the blood plasma and protects the Phytofare® against metabolization during the digestive process.
Callum Cottrell-Duffield, Vice President of PLPL, commented, "This first order from Coyne Healthcare represents a milestone for Plandaí since it launches ph2 as a new, commercially viable product. Since we first executed the license agreement with North West University to use Pheroid® in human use, we've been working to build nutriceutical applications. ph2™ contains all eight catechins which are protected by the Pheroid® until they reach the blood stream. Clinical testing has shown that, when entrapped in Pheroid®, the bioavailability increases an additional 30% over our already high levels while also extending the residency of the antioxidants in the bloodstream at therapeutic levels over 24 hours."
Kevin Coyne, Managing Director of Coyne Healthcare, added, "We expect our new product to be enthusiastically received by the market place once they understand the superiority of the extract which has been clinically proven to deliver much higher levels of antioxidants. Green Tea has thousands of studies supporting its various health benefits, we can now deliver Green Tea like never before, and this is the new benchmark in supplementation. We're excited to be launching this breakthrough in South Africa as its home market and soon thereafter expanding internationally".
Market Outlook:
The green tea leaf contains large amounts of polyphenols, such as flavonoids and catechin, which function as antioxidants for the body.
Studies have proven green tea has increased fat burning and boosts the metabolic rate.
The Global Weight Loss and Weight Management is estimated to reach $206.4 billion by 2019.
The Global Nutraceutical market was valued at $165.65 billion in 2014 and is expected to exceed $278 billion by 2021.
According to Transparency Market Research, the market will be propelled by soaring demands for functional food and beverages.
The global Cosmeceutical Market is estimated to be worth $650 billion by 2020.
Global Pharmaceutical sales are predicted to reach $1.3 trillion by 2018.
Technical Analysis:
PLPL is another one of those classic 'low risk, high reward' opportunities for traders.
The company is currently trading slightly above its 52-week low, and well below its 52-week high price of $0.29 per share.
A move back to $0.29 would represent gains of over +387%!
This is a highly volatile stock that once that ran up +2,500% from $0.12 to $3.12 per share in less than 6-weeks back in 2014/2015.
Could we be at the start of the next +1,000% rally for PLPL?
PLPL's strong sales outlook for Q2 and Q3 have us confident that the worst is over for this beaten down stock.
If today's after-hours news is any indication of the direction that the company is going, then we would have to say that the future appears very bright for PLPL.
Remember...
We've seen just 1 loser out of our last 16 picks.
In less than 2 months, those 15 winners have delivered as much as +1,223% in realistic profit!
We are urging all of our subscribers to add PLPL to their watchlist right now, and be ready to trade tomorrow morning when the clock strikes 9:30am EST!
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
For more information on PLPL, please visit their website: www.PlandaiBiotech.com
